MedTrace Logo

Effect of Sublingual Immunotherapy on Platlet factor4 Level in Children

NCT04851860 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2021-04-21

No results posted yet for this study

Summary

Better management and improving outcome of children with allergic rhinitis

Conditions

  • Allergic Rhinitis

Interventions

DRUG

sublingual immunotherapy

sublingual immunotherapy is the only disease modifying therapy preventing the evolution of AR to asthma

Sponsors & Collaborators

  • Zagazig University

    lead OTHER_GOV

Principal Investigators

  • Mohammad Romeh · Zagazig University

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
6 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-12
Primary Completion
2021-10-15
Completion
2021-11-20

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04851860 on ClinicalTrials.gov